Hormonal
Low-dose semaglutide (30 nmol/kg twice weekly) attenuates pathological cardiac and hepatic remodeling and improves exercise capacity in a rodent model of HFpEF independently of weight loss.
This preclinical study suggests that low-dose GLP-1 therapy may offer direct heart and liver protection in heart failure with preserved ejection fraction (HFpEF) without requiring weight loss. While promising, this is animal data; human application requires clinical validation.
In ZSF1 obese rats, low-dose semaglutide in the absence of weight loss, significantly improved cardiac function, exercise tolerance, and attenuated fibrosis in the heart and liver.
Why this rating
Preclinical rodent model (ZSF1 obese rats); not yet validated in human clinical trials for this specific low-dose protocol.
Source
Low Dose GLP-1 Therapy Attenuates Pathological Cardiac and Hepatic Remodelling in HFpEF Independent of Weight Loss
Mahmoud H. Elbatreek et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2025
DOI 10.1101/2025.09.26.678829
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →